Radius Health, Inc. (NASDAQ:RDUS) Shares Bought by BlackRock Inc.

BlackRock Inc. raised its stake in Radius Health, Inc. (NASDAQ:RDUS) by 98,245.6% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 2,630,745 shares of the biopharmaceutical company’s stock after buying an additional 2,628,070 shares during the period. BlackRock Inc. owned about 6.09% of Radius Health worth $101,679,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. C WorldWide Group Holding A S boosted its position in Radius Health by 0.6% in the first quarter. C WorldWide Group Holding A S now owns 7,397 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 43 shares during the period. Envestnet Asset Management Inc. boosted its position in Radius Health by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock valued at $163,000 after buying an additional 46 shares during the period. Principal Financial Group Inc. boosted its position in Radius Health by 3.1% in the first quarter. Principal Financial Group Inc. now owns 5,970 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 180 shares during the period. OppenheimerFunds Inc. boosted its position in Radius Health by 0.3% in the first quarter. OppenheimerFunds Inc. now owns 301,631 shares of the biopharmaceutical company’s stock valued at $11,658,000 after buying an additional 831 shares during the period. Finally, Swiss National Bank boosted its position in Radius Health by 2.1% in the first quarter. Swiss National Bank now owns 49,700 shares of the biopharmaceutical company’s stock valued at $1,921,000 after buying an additional 1,000 shares during the period. Institutional investors and hedge funds own 97.66% of the company’s stock.

Shares of Radius Health, Inc. (NASDAQ RDUS) opened at 35.52 on Friday. Radius Health, Inc. has a 52 week low of $31.58 and a 52 week high of $59.22. The firm’s market cap is $1.55 billion. The firm’s 50-day moving average price is $41.97 and its 200 day moving average price is $40.13.

Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by $0.23. The firm had revenue of $0.98 million for the quarter, compared to the consensus estimate of $1.96 million. During the same period in the prior year, the business earned ($1.01) EPS. Equities analysts anticipate that Radius Health, Inc. will post ($5.51) EPS for the current year.

WARNING: “Radius Health, Inc. (NASDAQ:RDUS) Shares Bought by BlackRock Inc.” was first published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.com-unik.info/2017/08/19/radius-health-inc-nasdaqrdus-stake-increased-by-blackrock-inc-updated-updated.html.

Several research firms recently commented on RDUS. Canaccord Genuity set a $85.00 price target on Radius Health and gave the stock a “buy” rating in a research note on Monday, July 17th. ValuEngine upgraded Radius Health from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. BidaskClub cut Radius Health from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Jefferies Group LLC cut their price target on Radius Health from $40.00 to $34.00 and set a “hold” rating on the stock in a research note on Tuesday, May 2nd. Finally, Cowen and Company cut Radius Health from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 2nd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. Radius Health has a consensus rating of “Hold” and a consensus price target of $53.60.

In other news, major shareholder Growth N. V. Biotech bought 60,000 shares of the business’s stock in a transaction dated Wednesday, August 16th. The stock was bought at an average price of $35.98 per share, for a total transaction of $2,158,800.00. Following the completion of the purchase, the insider now owns 5,248,799 shares of the company’s stock, valued at approximately $188,851,788.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Growth N. V. Biotech bought 40,000 shares of the business’s stock in a transaction dated Thursday, May 25th. The stock was purchased at an average price of $36.25 per share, with a total value of $1,450,000.00. Following the purchase, the insider now directly owns 4,998,799 shares of the company’s stock, valued at approximately $181,206,463.75. The disclosure for this purchase can be found here. Insiders bought 290,000 shares of company stock valued at $10,222,700 in the last quarter. 15.00% of the stock is currently owned by corporate insiders.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

What are top analysts saying about Radius Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Radius Health Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit